Lisinopril and Bone Health: What Women Need to Know About Density, Risk, and Life Stage

What Is Lisinopril and Why Do Women Take It?

Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor prescribed for hypertension, heart failure with reduced ejection fraction, and diabetic nephropathy or chronic kidney disease. In women, these indications overlap heavily with life-stage transitions: hypertension prevalence rises sharply after menopause, reaching approximately 75% of women by age 75, and CKD disproportionately affects women with a history of preeclampsia or lupus nephritis.

Lisinopril works by blocking the conversion of angiotensin I to angiotensin II, which lowers blood pressure, reduces aldosterone secretion, and decreases efferent arteriolar resistance in the kidney. What receives far less clinical attention is that angiotensin II receptors exist on osteoblasts and osteoclasts, meaning the renin-angiotensin-aldosterone system (RAAS) is an active participant in bone remodeling, not a bystander.

How the RAAS Connects to Bone Biology

The connection between the RAAS and skeletal metabolism is mechanistically straightforward once you know where to look.

Angiotensin II stimulates osteoclast differentiation and activity through AT1 receptors expressed on bone cells. In vitro and animal studies have consistently shown that angiotensin II promotes bone resorption, while ACE inhibitors or angiotensin receptor blockers reduce osteoclast-mediated mineral loss. Aldosterone, the downstream hormone that lisinopril indirectly suppresses by reducing angiotensin II, also increases urinary calcium excretion. Blocking aldosterone production, even partially, may reduce calcium wasting through the kidney.

This pathway is not a minor footnote. It is why researchers began asking, in the early 2000s, whether the tens of millions of patients taking ACE inhibitors were quietly receiving a skeletal side-benefit or, conversely, whether any disruption to RAAS signaling in bone cells might carry unintended consequences.

Why Estrogen Status Changes Everything

Estrogen suppresses renin secretion and dampens RAAS activity overall. Before menopause, your endogenous estrogen is already providing RAAS-modulating effects. After menopause, estrogen loss leads to RAAS upregulation, with postmenopausal women demonstrating higher circulating angiotensin II levels than premenopausal women at similar blood pressure readings. This means the pharmacological effect of lisinopril on RAAS, including any downstream effect on bone, is likely more pronounced in postmenopausal women than in younger women with intact estrogen signaling.

This is an area where evidence is extrapolated from mechanistic data rather than directly tested in large randomized trials specifically enrolling postmenopausal women and measuring bone mineral density (BMD) as a primary outcome. Be aware of that distinction as you read the evidence below.

What the Human Data Actually Shows on Bone Density

The evidence here is observational, not experimental. That matters for how you interpret findings and how you counsel patients or ask your clinician questions.

Observational Studies: A Consistent but Modest Signal

A 2012 meta-analysis of population-based cohort studies found that ACE inhibitor use was associated with a reduced risk of hip fracture, with a pooled odds ratio of approximately 0.84 compared with non-use. A 16% relative risk reduction sounds meaningful, but this finding comes from studies that could not fully control for confounders: people taking antihypertensives tend to have different baseline health behaviors, fall risk profiles, and comorbidities than people who are not.

A separate analysis using data from the Women's Health Initiative Observational Study examined BMD in women taking ACE inhibitors and found a statistically non-significant trend toward higher femoral neck BMD in ACE inhibitor users compared with non-users. The signal existed but was not strong enough to be conclusive in isolation.

The ALLHAT Context: What It Did and Did Not Tell Us

The ALLHAT trial (JAMA 2002) randomized 33,357 participants with hypertension and at least one cardiovascular risk factor to chlorthalidone, amlodipine, lisinopril, or doxazosin. The lisinopril arm showed equivalent cardiovascular mortality to chlorthalidone, though with a modestly higher stroke rate in Black participants and inferior outcomes in the doxazosin comparison. The trial enrolled approximately 47% women, making it more sex-inclusive than many antihypertensive trials of its era.

Critically, ALLHAT did not measure bone mineral density or fracture incidence as endpoints. Any extrapolation of ALLHAT data to bone health is indirect. What ALLHAT does provide is the safety and cardiovascular outcome context within which lisinopril is prescribed to millions of women today, including postmenopausal women who already face elevated fracture risk.

Sex-Specific Pharmacokinetics: Women Are Not Small Men

Women absorb lisinopril similarly to men but may have slightly higher plasma concentrations at equivalent weight-based doses due to lower renal clearance in some studies. The FDA label notes that women show approximately 20% higher lisinopril AUC than men at the same dose. Whether this pharmacokinetic difference translates to a meaningfully different bone effect has not been studied directly.

Perimenopause and Postmenopause: The Highest-Stakes Life Stage

The intersection of lisinopril use and bone health is most clinically significant in perimenopausal and postmenopausal women for three compounding reasons.

First, bone loss accelerates dramatically at menopause. Women can lose up to 20% of bone density in the five to seven years surrounding menopause, primarily from estrogen withdrawal disinhibiting osteoclast activity.

Second, hypertension becomes far more prevalent after menopause and lisinopril prescriptions correspondingly increase. You are most likely to be prescribed lisinopril at precisely the life stage when your bones are most vulnerable to loss.

Third, RAAS upregulation after menopause means the drug is acting on a more activated target system, as described above.

A practical framework for thinking about this: if you are a postmenopausal woman on lisinopril for hypertension, the drug is unlikely to be harming your bones and may be providing a small skeletal benefit through reduced osteoclast drive and lower urinary calcium loss. But lisinopril is not a substitute for evidence-based bone-protective strategies, and it should not delay discussion of DXA screening, calcium and vitamin D adequacy, resistance exercise, or, where appropriate, bisphosphonate or hormone therapy.

When to Ask for a DXA Scan

The U.S. Preventive Services Task Force recommends bone density screening for all women aged 65 and older, and for younger postmenopausal women whose fracture risk equals or exceeds that of a 65-year-old woman with no additional risk factors, estimated using the FRAX tool. Being on lisinopril does not change this recommendation, but it is a reminder to have the conversation with your clinician.

PCOS and Premenopausal Hypertension

Women with polycystic ovary syndrome (PCOS) are at higher risk for hypertension and metabolic syndrome at younger ages, sometimes landing on lisinopril in their 30s or early 40s. PCOS affects an estimated 6% to 12% of reproductive-age women in the United States. For these women, the bone health question is different: premenopausal bone density is generally preserved by adequate estrogen, but PCOS-related hyperandrogenism and menstrual irregularity can compromise bone accrual in some patients. Adding an ACE inhibitor does not meaningfully alter this picture, but it requires mandatory and reliable contraception (see the pregnancy section below).

Lisinopril and Calcium Metabolism

One underappreciated mechanism linking lisinopril to bone health is its effect on calcium handling.

Aldosterone promotes urinary calcium excretion through the kidney. By reducing angiotensin II and therefore aldosterone, lisinopril may decrease urinary calcium loss and increase the calcium available for bone mineralization. A small crossover study in hypertensive patients showed that ACE inhibition reduced 24-hour urinary calcium excretion by approximately 15% compared with baseline, a modest but directionally meaningful finding.

This is distinct from the calcium-sparing effect of thiazide diuretics, which act directly on the distal tubule. Lisinopril's calcium effect is indirect, mediated through aldosterone suppression, and smaller in magnitude than that of thiazides. Some women take both a thiazide and an ACE inhibitor for blood pressure control. In that combination, the calcium-sparing effects are additive but the combined effect on bone density has not been well-characterized in women specifically.

Vitamin D, PTH, and the ACE Inhibitor Interaction

One additional layer: ACE inhibitors may affect vitamin D metabolism. Angiotensin II appears to suppress renal 1-alpha-hydroxylase, the enzyme that converts 25-hydroxyvitamin D to its active form. Blocking angiotensin II with an ACE inhibitor may therefore slightly increase calcitriol production, which would further support calcium absorption and bone mineralization. This effect is modest and has not been replicated in large human trials, but it adds another mechanistic thread to the bone-protective hypothesis.

If you are taking lisinopril and have not had your 25-OH vitamin D level checked recently, that is a worthwhile conversation to have. The Endocrine Society recommends maintaining 25-OH vitamin D levels above 20 ng/mL for bone health, and many women, particularly those with darker skin or limited sun exposure, fall short of this.

Pregnancy and Lactation: A Hard Stop

Lisinopril is contraindicated throughout pregnancy. This is not a nuanced risk-benefit calculation. It is a firm contraindication.

First Trimester

The FDA originally classified lisinopril as Category D in the first trimester, meaning there is positive evidence of fetal risk but potential benefits might outweigh that risk in life-threatening situations. First-trimester ACE inhibitor exposure has been associated with a 2.71-fold increased risk of major congenital malformations, including cardiovascular and central nervous system defects, in a large Tennessee Medicaid cohort.

Second and Third Trimesters

The risk escalates severely after the first trimester. ACE inhibitors block fetal RAAS, which is essential for normal renal development. Exposure in the second or third trimester causes fetal renal tubular dysplasia, oligohydramnios, neonatal renal failure, hypocalvaria (underdeveloped skull bones), limb contractures, and death. The FDA assigned Category X for second and third trimester use. The drug must be stopped as soon as pregnancy is detected, and ideally before conception.

Contraception Requirement

Any woman of reproductive potential taking lisinopril requires reliable contraception. This includes:

• Women with PCOS who may ovulate unpredictably
• Perimenopausal women who retain fertility until 12 consecutive months of amenorrhea
• Women using lisinopril off-label for diabetic nephropathy in their reproductive years

Safe antihypertensive alternatives in pregnancy include labetalol, nifedipine, and methyldopa. ACOG Practice Bulletin No. 203 identifies these three agents as first-line options for chronic hypertension in pregnancy.

Lactation

Lisinopril is present in breast milk. The LactMed database lists lisinopril as not recommended during breastfeeding due to limited safety data and the availability of better-studied alternatives. Captopril and enalapril have more human lactation data and are generally preferred if an ACE inhibitor is specifically needed postpartum, though nifedipine or labetalol remains preferable for most postpartum hypertension.

Who This Is Right for and Who Should Think Twice

Women Who May Be Well-Suited to Lisinopril

• Postmenopausal women with hypertension and elevated cardiovascular risk. The ALLHAT data supports efficacy, and the possible bone-neutral-to-modest-protective effect is reassuring.
• Women with diabetic nephropathy or proteinuric CKD. The renal-protective effect of ACE inhibition is among the best-characterized drug benefits in this group, and ACOG guidance supports ACE inhibitors as first-line nephroprotective agents outside of pregnancy.
• Women with heart failure with reduced ejection fraction. ACE inhibitors reduce all-cause mortality in this population regardless of sex, per the foundational SOLVD trials.
• Postmenopausal women on bisphosphonates for osteoporosis. Adding lisinopril for comorbid hypertension does not interact with bisphosphonate therapy and may provide complementary RAAS-mediated bone benefit.

Women Who Need a Different Conversation

• Any woman who is pregnant, planning pregnancy within 12 months, or not using reliable contraception. Full stop.
• Women in perimenopause who are still having cycles. The contraception conversation is mandatory.
• Women with a history of angioedema. ACE inhibitor-induced angioedema is more common in women than men, with some estimates suggesting women have a two- to fourfold higher risk. ARBs carry lower angioedema risk and are a reasonable alternative.
• Women with bilateral renal artery stenosis or solitary kidney. Contraindicated.
• Women with hyperkalemia or severe renal impairment (eGFR <30 mL/min/1.73m²). Requires specialist guidance before initiation.

Clinical Evidence Gap: Where Women Are Underrepresented

ALLHAT enrolled 47% women, better than most trials of its era, but women remain underrepresented in cardiovascular drug trials overall, comprising roughly 30% of participants in landmark hypertension studies through the 1990s. The bone health sub-question is even thinner: no dedicated RCT has randomized women to lisinopril versus placebo or an active comparator and measured BMD or fracture as a primary endpoint.

As The Menopause Society's 2023 position statement on cardiovascular health notes, "antihypertensive therapy selection in postmenopausal women should account for the hormonal context of RAAS activation after estrogen loss," yet few prescribing guidelines include this language in practice.

What this means practically: the bone-protective signal for lisinopril in women is biologically plausible and directionally consistent across observational data, but it is extrapolated rather than proven in randomized controlled trials with women as the primary study population. Prescribe and take it for its established cardiovascular and renal indications, not for skeletal benefit.

Monitoring and Practical Management for Women on Lisinopril

Your prescriber should check the following at baseline and on a schedule:

| Parameter | Frequency | Notes for Women | |---|---|---| | Blood pressure | At initiation, 2-4 weeks after dose change, then every 3-6 months | Target <130/80 mmHg per ACC/AHA 2017 | | Serum creatinine and eGFR | Baseline, 1-2 weeks after initiation or dose increase, then every 6-12 months | Expect up to 30% rise in creatinine; acceptable if stable | | Serum potassium | Baseline, 1-2 weeks after initiation, then every 6 months | Risk increases if also on spironolactone, common in women with PCOS or heart failure | | 25-OH vitamin D | Annually | Supplement to achieve >20 ng/mL for bone health | | DXA bone density | Per USPSTF schedule | Do not delay screening because of ACE inhibitor use | | Urine protein (dipstick or ACR) | Annually in diabetic or CKD patients | ACE inhibitor is cardioprotective in proteinuric CKD | | Pregnancy test | If contraception is uncertain or a period is missed | ACE inhibitor must be stopped immediately |

Cough is the most common side effect of lisinopril, affecting approximately 10% to 15% of users overall, with women experiencing it roughly twice as often as men. It is not dangerous, but it is persistently underrecognized as drug-related in women, where it is sometimes attributed to GERD or postnasal drip. If you develop a dry, persistent cough after starting lisinopril, tell your prescriber. Switching to an angiotensin receptor blocker such as losartan or valsartan eliminates the cough while preserving similar cardiovascular and renal protection.